Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock TopplesInvestors Business Daily • 02/03/23
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestoneGlobeNewsWire • 02/03/23
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitisGlobeNewsWire • 01/30/23
Regeneron, Sanofi's Dupixent is one step closer to approval for young children in EuropeMarket Watch • 01/27/23
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitisGlobeNewsWire • 01/27/23
Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia AGlobeNewsWire • 01/25/23
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023The Motley Fool • 01/23/23
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcarePRNewsWire • 01/18/23